Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Nanobiotix S.A.NASDAQ: NBTX

Revenue · Q4 FY2025 · quarter ended Dec 2025

Revenue turns positive

Q4 FY2025 revenue was €3.01M, compared with -€16.48M a year earlier. Over 3 fiscal years it compounded at +83.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of €25.46M (-14.1%) for the fiscal year ending Dec 2026, a slowdown from the +512.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
€3.01M— QoQ
Last fiscal yearDec 2025
€29.64M+512.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+118.2%——
1 year+512.3%-14.1%-526.4 pp
3-year CAGR+83.8%+47.2%-36.6 pp
5-year CAGR+37.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
29.64M EUR
Year-over-year change
+512.3%
4-year CAGR
+82.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +512.3% is the highest of 6, against a peer median of +5.4%.
  • Over three fiscal years its annual growth of +83.8% compares with a peer median of +339.3%.
NBTX Competitors
Revenue for NBTX and competitors
Company Period LTM YoY 3-year CAGR
PBYIPuma Biotechnology, Inc.LTM Mar 2026$227.18M USD-2.4%+0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$217.17M USD+396.7%—
IBRXImmunityBio, Inc.LTM Sep 2026$182.57M USD+121.2%+678.6%
KURAKura Oncology, Inc.LTM Mar 2026$71.64M USD+5.4%—
NBTXNanobiotix S.A.FY2025€29.64M EUR+512.3%+83.8%
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD——
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD——
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD——
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—
Peer median (excluding NBTX) —+5.4%+339.3%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.